flecainide has been researched along with vernakalant in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (88.24) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Allison, B; Gibson, JK; Pourrier, M; Yang, Y | 1 |
| Avetisyan, R; Bash, LD; Buono, JL; Davies, GM; Fahrbach, K; Martin, A; Mwamburi, M; Phatak, H | 1 |
| Beatch, GN; Gleim, GW; Lynch, JJ; Morabito, CJ; Regan, CP | 1 |
| Aragon, M; Caro, M; Conde, D; Costabel, JP; Ferro, A; Giniger, A; Klein, A; Trivi, M | 1 |
| Caro, M; Conde, D; Corrales Barboza, A; Costabel, JP; Ferro, A; Lambardi, F; Lavalle Cobo, A; Trivi, M | 1 |
| Conde, D | 1 |
| Aragon, M; Conde, D; Costabel, JP; Lambardi, F; Trivi, M | 1 |
| Auricchio, A; Houthuizen, P; Kuiper, M; Maessen, JG; Prinzen, FW; Strik, M; van Middendorp, LB | 2 |
| Christ, T | 1 |
| Tikhonov, DB; Zhorov, BS | 1 |
| Katus, HA; Li, J; Schweizer, PA; Seyler, C; Thomas, D | 1 |
| Katus, HA; Schweizer, PA; Seyler, C; Thomas, D; Zitron, E | 1 |
| Hartikainen, J; Heikkola, A; Hyppölä, H; Lekkala, M; Pohjantähti-Maaroos, H; Sinisalo, E | 1 |
| Chen, R; Chung, SH | 1 |
| Deftereos, S; Doundoulakis, I; Gatzoulis, KA; Kordalis, A; Pagkalidou, E; Stefanadis, C; Tsiachris, D; Tsioufis, K | 1 |
| Bove, T; Cilenti, F; Copetti, R; Cristiani, L; Guglielmo, N; Orso, D; Santangelo, S | 1 |
3 review(s) available for flecainide and vernakalant
| Article | Year |
|---|---|
Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.
Topics: Aged; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Bayes Theorem; Electric Countershock; Female; Flecainide; Humans; Male; Middle Aged; Propafenone; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Pharmacologic Cardioversion in Patients with Paroxysmal Atrial Fibrillation: A Network Meta-Analysis.
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Pyrrolidines; Randomized Controlled Trials as Topic | 2021 |
Bayesian Network Meta-analysis of Randomized Controlled Trials on the Efficacy of Antiarrhythmics in the Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; Humans; Network Meta-Analysis; Quinidine; Randomized Controlled Trials as Topic; Ranolazine; Systematic Reviews as Topic; Verapamil | 2023 |
14 other study(ies) available for flecainide and vernakalant
| Article | Year |
|---|---|
Comparison of the in vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model.
Topics: Animals; Anisoles; Anti-Arrhythmia Agents; Aorta, Abdominal; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Flecainide; Hindlimb; Male; Pyrrolidines; Rats; Rats, Sprague-Dawley; Vascular Resistance | 2011 |
Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues.
Topics: Anisoles; Anti-Arrhythmia Agents; Arteries; Cardiotonic Agents; Cardiotoxins; Flecainide; Heart Ventricles; Humans; In Vitro Techniques; Myocardial Contraction; Osmolar Concentration; Pyrrolidines; Skin; Sodium Potassium Chloride Symporter Inhibitors; Vascular Resistance; Vasodilation; Vasodilator Agents | 2013 |
Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation.
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Europe; Flecainide; Humans; Practice Guidelines as Topic; Propafenone; Pyrrolidines | 2013 |
Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation.
Topics: Aged; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Time Factors | 2013 |
Conversion of recent onset atrial fibrillation: which drug is faster?
Topics: Administration, Oral; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Injections, Intravenous; Propafenone; Pyrrolidines; Time Factors | 2013 |
Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation.
Topics: Administration, Oral; Aged; Anisoles; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flecainide; Health Status; Humans; Injections, Intravenous; Male; Middle Aged; Perception; Propafenone; Prospective Studies; Pyrrolidines; Quality of Life; Treatment Outcome; Voltage-Gated Sodium Channel Blockers | 2014 |
Electrophysiological and hemodynamic effects of vernakalant and flecainide during cardiac resynchronization in dyssynchronous canine hearts.
Topics: Animals; Anisoles; Anti-Arrhythmia Agents; Blood Pressure; Bundle-Branch Block; Cardiac Pacing, Artificial; Cardiac Resynchronization Therapy; Dogs; Electrocardiography; Electrophysiological Phenomena; Female; Flecainide; Heart Rate; Hemodynamics; Male; Pyrrolidines; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Atrial-selective antiarrhythmic activity by vernakalant fact or fiction?
Topics: Animals; Anisoles; Anti-Arrhythmia Agents; Cardiac Resynchronization Therapy; Electrophysiological Phenomena; Female; Flecainide; Hemodynamics; Male; Pyrrolidines | 2014 |
Homology modeling of Kv1.5 channel block by cationic and electroneutral ligands.
Topics: Anesthetics, Local; Anisoles; Benzocaine; Biphenyl Compounds; Flecainide; Humans; Kv1.3 Potassium Channel; Models, Molecular; Potassium Channel Blockers; Protein Conformation; Pyrrolidines; Voltage-Gated Sodium Channel Blockers | 2014 |
Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
Topics: Animals; Anisoles; Anti-Arrhythmia Agents; CHO Cells; Cricetinae; Cricetulus; Female; Flecainide; Humans; Oocytes; Potassium Channel Blockers; Potassium Channels, Tandem Pore Domain; Pyrrolidines; Xenopus laevis | 2014 |
Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts.
Topics: Action Potentials; Animals; Anisoles; Anti-Arrhythmia Agents; Blood Pressure; Bundle-Branch Block; Chronic Disease; Disease Models, Animal; Dogs; Electrophysiologic Techniques, Cardiac; Female; Flecainide; Heart Conduction System; Hemodynamics; Male; Myocardial Contraction; Pyrrolidines; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2014 |
Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.
Topics: Action Potentials; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; CHO Cells; Cricetinae; Cricetulus; Flecainide; Humans; Membrane Potentials; Oocytes; Patch-Clamp Techniques; Potassium Channels, Tandem Pore Domain; Pyrrolidines; Xenopus laevis | 2014 |
Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Resynchronization Therapy; Dose-Response Relationship, Drug; Female; Flecainide; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Time Factors; Treatment Outcome | 2019 |
Inhibition of Voltage-Gated K
Topics: Amino Acid Sequence; Anisoles; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Binding Sites; Crystallography, X-Ray; Ficusin; Flecainide; Humans; Kv1.5 Potassium Channel; Molecular Dynamics Simulation; Protein Conformation; Pyrrolidines; Sequence Homology, Amino Acid | 2018 |